{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T21:02:26Z","timestamp":1791925346367,"version":"4.3.4"},"reference-count":95,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010876","name":"Shanghai University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["23KFL017"],"award-info":[{"award-number":["23KFL017"]}],"id":[{"id":"10.13039\/501100010876","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai Municipality","doi-asserted-by":"publisher","award":["24ZR1466600"],"award-info":[{"award-number":["24ZR1466600"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ijbiomac.2025.141392","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T02:57:27Z","timestamp":1740106647000},"page":"141392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"P1","title":["Sphingosine kinase 2 in cancer: A review of its expression, function, and inhibitor development"],"prefix":"10.1016","volume":"306","author":[{"given":"Yanqun","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2025.141392_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115296","article-title":"Regulation of membrane phospholipid biosynthesis in mammalian cells","volume":"206","author":"Morita","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0010","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pharmthera.2018.10.011","article-title":"The sphingosine kinase-1\/sphingosine-1-phosphate axis in cancer: potential target for anticancer therapy","volume":"195","author":"Zheng","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"6585","key":"10.1016\/j.ijbiomac.2025.141392_bb0015","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/381800a0","article-title":"Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate","volume":"381","author":"Cuvillier","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1186\/s12935-019-1014-8","article-title":"Roles of sphingosine-1-phosphate signaling in cancer","volume":"19","author":"Wang","year":"2019","journal-title":"Cancer Cell Int."},{"issue":"5945","key":"10.1016\/j.ijbiomac.2025.141392_bb0025","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1126\/science.1176709","article-title":"Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate","volume":"325","author":"Hait","year":"2009","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.141392_bb0030","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/biof.1030","article-title":"Sphingosine-1-phosphate signaling in physiology and diseases","volume":"38","author":"Takuwa","year":"2012","journal-title":"Biofactors"},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0035","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1146\/annurev-biochem-013118-111902","article-title":"Exosomes","volume":"88","author":"Pegtel","year":"2019","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113164","article-title":"Rational design of SphK inhibitors using crystal structures aided by computer","volume":"213","author":"Ding","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2020.127900","article-title":"Investigating the binding mechanism of sphingosine kinase 1\/2 inhibitors: insights into subtype selectivity by homology modeling, molecular dynamics simulation and free energy calculation studies","volume":"1208","author":"Zhang","year":"2020","journal-title":"J. Mol. Struct."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.141392_bb0050","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1021\/acsmedchemlett.5b00304","article-title":"Structure-activity relationship studies and molecular modeling of naphthalene-based sphingosine kinase 2 inhibitors","volume":"7","author":"Congdon","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"issue":"D1","key":"10.1016\/j.ijbiomac.2025.141392_bb0055","doi-asserted-by":"crossref","first-page":"D609","DOI":"10.1093\/nar\/gkae1010","article-title":"UniProt: the universal protein knowledgebase in 2025","volume":"53","author":"T.U. Consortium","year":"2025","journal-title":"Nucleic Acids Res."},{"issue":"W1","key":"10.1016\/j.ijbiomac.2025.141392_bb0060","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: homology modelling of protein structures and complexes","volume":"46","author":"Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.141392_bb0065","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141392_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-023-02874-z","article-title":"RPTOR blockade suppresses brain metastases of NSCLC by interfering the ceramide metabolism via hijacking YY1 binding","volume":"43","author":"Lin","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141392_bb0075","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s13277-013-1051-1","article-title":"Prognostic significance of sphingosine kinase 2 expression in non-small cell lung cancer","volume":"35","author":"Wang","year":"2014","journal-title":"Tumour Biol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.141392_bb0080","doi-asserted-by":"crossref","first-page":"850","DOI":"10.3390\/cancers16050850","article-title":"Critical roles of the sphingolipid metabolic pathway in liver regeneration, hepatocellular carcinoma progression and therapy","volume":"16","author":"Nojima","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0085","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141392_bb0090","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41389-022-00444-0","article-title":"Ablation of sphingosine kinase 2 suppresses fatty liver-associated hepatocellular carcinoma via downregulation of ceramide transfer protein","volume":"11","author":"Liu","year":"2022","journal-title":"Oncogenesis"},{"issue":"10251","key":"10.1016\/j.ijbiomac.2025.141392_bb0095","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.ijbiomac.2025.141392_bb0100","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1038\/s41388-021-01753-1","article-title":"METTL3-mediated m(6)a methylation of SPHK2 promotes gastric cancer progression by targeting KLF2","volume":"40","author":"Huo","year":"2021","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.141392_bb0105","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1007\/s10528-021-10166-4","article-title":"miR-153-3p attenuates the development of gastric Cancer by suppressing SphK2","volume":"60","author":"Jia","year":"2022","journal-title":"Biochem. Genet."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.141392_bb0110","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3390\/cancers14030535","article-title":"Targeting chronic inflammation of the digestive system in Cancer prevention: modulators of the bioactive sphingolipid Sphingosine-1-phosphate pathway","volume":"14","author":"McGowan","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.141392_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101174","article-title":"Global colorectal cancer burden in 2020 and projections to 2040","volume":"14","author":"Xi","year":"2021","journal-title":"Transl. Oncol."},{"issue":"29","key":"10.1016\/j.ijbiomac.2025.141392_bb0120","doi-asserted-by":"crossref","first-page":"5214","DOI":"10.1038\/s41388-020-1352-y","article-title":"SphK2 confers 5-fluorouracil resistance to colorectal cancer via upregulating H3K56ac-mediated DPD expression","volume":"39","author":"Zhang","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0125","doi-asserted-by":"crossref","unstructured":"A.V. Nguyen, Y.Y. Wu, E.Y. Lin, STAT3 and sphingosine-1-phosphate in inflammation-associated colorectal cancer, World J. Gastroenterol. 20(30) (2014) 10279\u201387.","DOI":"10.3748\/wjg.v20.i30.10279"},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0130","doi-asserted-by":"crossref","unstructured":"X. Ding, R. Chaiteerakij, C.D. Moser, H. Shaleh, J. Boakye, G. Chen, A. Ndzengue, Y. Li, Y. Zhou, S. Huang, F.A. Sinicrope, X. Zou, M.B. Thomas, C.D. Smith, L.R. Roberts, Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells, Oncotarget 7(15) (2016) 20080\u201392.","DOI":"10.18632\/oncotarget.7914"},{"issue":"10074","key":"10.1016\/j.ijbiomac.2025.141392_bb0135","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of triple-negative breast Cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0145","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.598218","article-title":"SphK2\/S1P promotes metastasis of triple-negative breast Cancer through the PAK1\/LIMK1\/Cofilin1 signaling pathway","volume":"8","author":"Shi","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0150","doi-asserted-by":"crossref","unstructured":"D.K. Armstrong, R.D. Alvarez, J.N. Bakkum-Gamez, L. Barroilhet, K. Behbakht, A. Berchuck, L.M. Chen, M. Cristea, M. DeRosa, E.L. Eisenhauer, D.M. Gershenson, H.J. Gray, R. Grisham, A. Hakam, A. Jain, A. Karam, G.E. Konecny, C.A. Leath, J. Liu, H. Mahdi, L. Martin, D. Matei, M. McHale, K. McLean, D.S. Miller, D.M. O'Malley, S. Percac-Lima, E. Ratner, S.W. Remmenga, R. Vargas, T.L. Werner, E. Zsiros, J.L. Burns, A.M. Engh, Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw 19(2) (2021) 191\u2013226.","DOI":"10.6004\/jnccn.2021.0007"},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.141392_bb0155","doi-asserted-by":"crossref","first-page":"645","DOI":"10.21037\/atm-20-6742","article-title":"Inhibition of sphingosine kinase 2 down-regulates ERK\/c-Myc pathway and reduces cell proliferation in human epithelial ovarian cancer","volume":"9","author":"Dai","year":"2021","journal-title":"Ann Transl Med"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141392_bb0160","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1515\/med-2022-0422","article-title":"Activation of SphK2 contributes to adipocyte-induced EOC cell proliferation","volume":"17","author":"Dai","year":"2022","journal-title":"Open Med (Wars)"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.141392_bb0165","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjh.16530","article-title":"Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1","volume":"190","author":"LeBlanc","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.141392_bb0170","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2016.208","article-title":"Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies","volume":"30","author":"Evangelisti","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0175","volume":"8","author":"Diaz Escarcega","year":"2021","journal-title":"The Functional Role of Sphingosine Kinase 2, Front Mol Biosci"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.141392_bb0180","doi-asserted-by":"crossref","first-page":"8162","DOI":"10.1002\/jcp.27612","article-title":"New insights into the roles and regulation of SphK2 as a therapeutic target in cancer chemoresistance","volume":"234","author":"Hasanifard","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"40","key":"10.1016\/j.ijbiomac.2025.141392_bb0185","doi-asserted-by":"crossref","first-page":"64886","DOI":"10.18632\/oncotarget.11714","article-title":"An oncogenic role for sphingosine kinase 2","volume":"7","author":"Neubauer","year":"2016","journal-title":"Oncotarget"},{"issue":"47","key":"10.1016\/j.ijbiomac.2025.141392_bb0190","doi-asserted-by":"crossref","first-page":"46832","DOI":"10.1074\/jbc.M306577200","article-title":"Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis","volume":"278","author":"Igarashi","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.141392_bb0195","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1182\/blood-2014-03-559385","article-title":"Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma","volume":"124","author":"Venkata","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.141392_bb0200","first-page":"546","article-title":"Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2\/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma","volume":"9","author":"Ding","year":"2019","journal-title":"Am. J. Cancer Res."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.141392_bb0205","first-page":"343","article-title":"The m6A writers regulated by the IL-6\/STAT3 inflammatory pathway facilitate cancer cell stemness in cholangiocarcinoma","volume":"19","author":"Ye","year":"2021","journal-title":"Cancer Biol. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141392_bb0210","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrc.2017.96","article-title":"Sphingolipid metabolism in cancer signalling and therapy","volume":"18","author":"Ogretmen","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"13","key":"10.1016\/j.ijbiomac.2025.141392_bb0215","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/sj.onc.1204187","article-title":"Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists","volume":"20","author":"Kranenburg","year":"2001","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.141392_bb0220","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40291-019-00401-5","article-title":"S1PR1 as a novel promising therapeutic target in Cancer therapy","volume":"23","author":"Rostami","year":"2019","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0225","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jconrel.2018.07.039","article-title":"Sphk2 RNAi nanoparticles suppress tumor growth via downregulating cancer cell derived exosomal microRNA","volume":"286","author":"Liang","year":"2018","journal-title":"J. Control. Release"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.141392_bb0230","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1158\/0008-5472.CAN-13-2732","article-title":"Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression","volume":"74","author":"Wallington-Beddoe","year":"2014","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.141392_bb0235","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1007\/s13277-015-4700-8","article-title":"Sphingosine kinase 2 promotes colorectal cancer cell proliferation and invasion by enhancing MYC expression","volume":"37","author":"Zhang","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0240","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.semcancer.2019.09.007","article-title":"Skvortsova, II, Cancer stem cells and their unique role in metastatic spread","volume":"60","author":"Steinbichler","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"15","key":"10.1016\/j.ijbiomac.2025.141392_bb0245","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood.2022016112","article-title":"Loss of sphingosine kinase 2 promotes the expansion of hematopoietic stem cells by improving their metabolic fitness","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.141392_bb0250","doi-asserted-by":"crossref","first-page":"341","DOI":"10.15761\/JTS.1000341","article-title":"Resistance to drugs and cell death in cancer stem cells (CSCs)","volume":"6","author":"Safa","year":"2020","journal-title":"J Transl Sci"},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2023.148063","article-title":"The accumulation of sphingosine kinase 2 disrupts the DNA damage response and promotes resistance to genotoxic agents","volume":"897","author":"da Silva","year":"2024","journal-title":"Gene"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.141392_bb0260","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.bbalip.2019.05.008","article-title":"Sphingosine kinase 2 is a negative regulator of inflammatory macrophage activation","volume":"1864","author":"Weigert","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.141392_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100631","article-title":"The sphingosine kinase 2 inhibitors ABC294640 and K145 elevate (dihydro)sphingosine 1-phosphate levels in various cells","volume":"65","author":"Prell","year":"2024","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.141392_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100510","article-title":"Nuclear SphK2\/S1P signaling is a key regulator of ApoE production and A\u03b2 uptake in astrocytes","volume":"65","author":"Komai","year":"2024","journal-title":"J. Lipid Res."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.141392_bb0275","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1016\/j.bbadis.2018.09.007","article-title":"Sphingosine kinase 2 cooperating with Fyn promotes kidney fibroblast activation and fibrosis via STAT3 and AKT","volume":"1864","author":"Zhu","year":"2018","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"issue":"40","key":"10.1016\/j.ijbiomac.2025.141392_bb0280","article-title":"Sphingosine kinase 2 regulates aryl hydrocarbon receptor nuclear translocation and target gene activation","volume":"11","author":"Yokoyama","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0285","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40364-018-0120-4","article-title":"Sphingosine kinase 2 supports the development of BCR\/ABL-independent acute lymphoblastic leukemia in mice","volume":"6","author":"Xie","year":"2018","journal-title":"Biomark. Res."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.141392_bb0290","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.annonc.2021.01.074","article-title":"Exosome-based liquid biopsies in cancer: opportunities and challenges","volume":"32","author":"Yu","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0295","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4806541","article-title":"The role of Sphingosine-1-phosphate and Ceramide-1-phosphate in inflammation and Cancer","volume":"2017","author":"Hait","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0300","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.biocel.2016.02.018","article-title":"SIRT1 mediates Sphk1\/S1P-induced proliferation and migration of endothelial cells","volume":"74","author":"Gao","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.141392_bb0305","first-page":"213","article-title":"Sphingosine 1-phosphate and its regulatory role in vascular endothelial cells","volume":"37","author":"Qiu","year":"2022","journal-title":"Histol. Histopathol."},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0310","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12957-016-0884-7","article-title":"The SphKs\/S1P\/S1PR1 axis in immunity and cancer: more ore to be mined","volume":"14","author":"Jin","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0315","doi-asserted-by":"crossref","first-page":"6917","DOI":"10.2147\/IJN.S264498","article-title":"Exosome: a review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications","volume":"15","author":"Zhang","year":"2020","journal-title":"Int. J. Nanomedicine"},{"issue":"20","key":"10.1016\/j.ijbiomac.2025.141392_bb0320","doi-asserted-by":"crossref","first-page":"7571","DOI":"10.3390\/ijms21207571","article-title":"From 1957 to nowadays: a brief history of epigenetics","volume":"21","author":"Peixoto","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.141392_bb0325","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1093\/bib\/bby054","article-title":"Trends in the development of miRNA bioinformatics tools","volume":"20","author":"Chen","year":"2019","journal-title":"Brief. Bioinform."},{"issue":"26","key":"10.1016\/j.ijbiomac.2025.141392_bb0330","doi-asserted-by":"crossref","first-page":"39907","DOI":"10.18632\/oncotarget.9530","article-title":"MicroRNA-613 inhibits cell growth, migration and invasion of papillary thyroid carcinoma by regulating SphK2","volume":"7","author":"Qiu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0335","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.biopha.2018.06.052","article-title":"MiR-363-3p suppresses tumor growth and metastasis of colorectal cancer via targeting SphK2","volume":"105","author":"Dong","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0340","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12935-017-0415-9","article-title":"MicroRNA-338-3p suppresses cell proliferation and induces apoptosis of non-small-cell lung cancer by targeting sphingosine kinase 2","volume":"17","author":"Zhang","year":"2017","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141392_bb0345","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41420-023-01320-5","article-title":"Nuclear SPHK2\/S1P induces oxidative stress and NLRP3 inflammasome activation via promoting p53 acetylation in lipopolysaccharide-induced acute lung injury","volume":"9","author":"Gong","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0350","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jconrel.2022.07.018","article-title":"Challenges for the application of EGFR-targeting peptide GE11 in tumor diagnosis and treatment","volume":"349","author":"Hailing","year":"2022","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.141392_bb0355","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.apsb.2014.12.009","article-title":"Bile acids and sphingosine-1-phosphate receptor 2 in hepatic lipid metabolism","volume":"5","author":"Kwong","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"issue":"16","key":"10.1016\/j.ijbiomac.2025.141392_bb0360","first-page":"4642","article-title":"A phase I study of ABC294640, a first-in-class sphingosine Kinase-2 inhibitor","volume":"23","author":"Britten","year":"2017","journal-title":"Patients with Advanced Solid Tumors, Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141392_bb0365","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13046-015-0205-y","article-title":"Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo","volume":"34","author":"Xun","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.141392_bb0370","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056471","article-title":"Biological characterization of 3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione (K145) as a selective sphingosine kinase-2 inhibitor and anticancer agent","volume":"8","author":"Liu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2021.09.060","article-title":"The alleviating effect of sphingosine kinases 2 inhibitor K145 on nonalcoholic fatty liver","volume":"580","author":"Shi","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112713","article-title":"Structure-activity relationship studies and bioactivity evaluation of 1,2,3-triazole containing analogues as a selective sphingosine kinase-2 inhibitors","volume":"206","author":"Tangadanchu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116577","article-title":"Discovery and biological evaluation of biaryl acetamide derivatives as selective and in vivo active sphingosine kinase-2 inhibitors","volume":"275","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.141392_bb0390","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1021\/acsbiomedchemau.2c00017","article-title":"Sphingosine kinase 2 inhibitors: rigid aliphatic tail derivatives deliver potent and selective analogues","volume":"2","author":"Pashikanti","year":"2022","journal-title":"ACS Bio Med Chem Au"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.141392_bb0395","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1124\/jpet.115.225862","article-title":"Sphingosine kinase 2 inhibition and blood sphingosine 1-phosphate levels","volume":"355","author":"Kharel","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.141392_bb0400","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.bbrc.2017.04.100","article-title":"Dual sphingosine kinase inhibitor SKI-II enhances sensitivity to 5-fluorouracil in hepatocellular carcinoma cells via suppression of osteopontin and FAK\/IGF-1R signalling","volume":"487","author":"Grb\u010di\u0107","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.141392_bb0405","doi-asserted-by":"crossref","first-page":"7065","DOI":"10.18632\/oncotarget.3178","article-title":"A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties","volume":"6","author":"Pitman","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.141392_bb0410","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/micc.12271","article-title":"Examining the role of sphingosine Kinase-2 in the regulation of endothelial cell barrier integrity","volume":"23","author":"Dimasi","year":"2016","journal-title":"Microcirculation"},{"issue":"16","key":"10.1016\/j.ijbiomac.2025.141392_bb0415","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1016\/j.bmcl.2013.06.030","article-title":"Structure guided design of a series of sphingosine kinase (SphK) inhibitors","volume":"23","author":"Gustin","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.141392_bb0420","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1124\/jpet.114.219659","article-title":"The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines","volume":"352","author":"Dick","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"19","key":"10.1016\/j.ijbiomac.2025.141392_bb0425","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1016\/j.bmc.2014.07.044","article-title":"Design, synthesis and evaluation of 2-aminothiazole derivatives as sphingosine kinase inhibitors","volume":"22","author":"Vogt","year":"2014","journal-title":"Bioorg. Med. Chem."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.141392_bb0430","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s41419-022-05049-4","article-title":"Targeting sphingosine kinase 1\/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth","volume":"13","author":"Xue","year":"2022","journal-title":"Cell Death Dis."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.141392_bb0435","doi-asserted-by":"crossref","first-page":"524","DOI":"10.4161\/cbt.11.5.14677","article-title":"Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts","volume":"11","author":"Beljanski","year":"2011","journal-title":"Cancer Biol. Ther."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.141392_bb0440","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1080\/15384047.2015.1056944","article-title":"ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer","volume":"16","author":"Yang","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0445","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1148932","article-title":"FTY720 in immuno-regenerative and wound healing technologies for muscle, epithelial and bone regeneration","volume":"14","author":"Behara","year":"2023","journal-title":"Front. Physiol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.141392_bb0450","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/jcmm.12635","article-title":"The antineoplastic properties of FTY720: evidence for the repurposing of fingolimod","volume":"19","author":"Patmanathan","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0455","doi-asserted-by":"crossref","unstructured":"L. Cao, M. Li, L. Yao, P. Yan, X. Wang, Z. Yang, Y. Lao, H. Li, K. Yang, K. Li, Siponimod for multiple sclerosis, Cochrane Database Syst Rev 11(11) (2021) Cd013647.","DOI":"10.1002\/14651858.CD013647.pub2"},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.141392_bb0460","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s40265-020-01319-7","article-title":"Ozanimod: First Approval","volume":"80","author":"Lamb","year":"2020","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.141392_bb0465","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bcp.12129","article-title":"Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study","volume":"76","author":"Brossard","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.141392_bb0470","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40265-024-01997-7","article-title":"Etrasimod: first approval","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ijbiomac.2025.141392_bb0475","doi-asserted-by":"crossref","first-page":"694","DOI":"10.3389\/fonc.2020.00694","article-title":"Targeting SphK2 reverses acquired resistance of Regorafenib in hepatocellular carcinoma","volume":"10","author":"Shi","year":"2020","journal-title":"Front. Oncol."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025019439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025019439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:47:57Z","timestamp":1782902877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025019439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":95,"alternative-id":["S0141813025019439"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.141392","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sphingosine kinase 2 in cancer: A review of its expression, function, and inhibitor development","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.141392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"141392"}}